Real-world outcomes of trastuzumab plus chemotherapy in HER2-positive biliary tract cancers from a high-incidence region. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results